Literature DB >> 18698086

Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial.

Ersi Voskaridou, Dimitrios Christoulas, Marialena Konstantinidou, Evangelos Tsiftsakis, Panagiotis Alexakos, Evangelos Terpos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18698086     DOI： 10.3324/haematol.12849

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients.

Authors:  Omid Reza Zekavat; Mohamadreza Bordbar; Sezaneh Haghpanah; Forough Saki; Asghar Bazrafshan; Haleh Bozorgi
Journal:  J Bone Miner Metab       Date:  2019-04-11       Impact factor: 2.626

2.  Safety of Zoledronic Acid in Patients with Thalassemia Associated Low Bone Mineral Density.

Authors:  Rahul Naithani; Tulika Seth; Nikhil Tandon; Jagdish Chandra; H Pati; V P Choudhry
Journal:  Indian J Hematol Blood Transfus       Date:  2017-08-09       Impact factor: 0.900

Review 3.  Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Authors:  S Ferrari; M L Bianchi; J A Eisman; A J Foldes; S Adami; D A Wahl; J J Stepan; M-C de Vernejoul; J-M Kaufman
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

4.  Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration.

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Charoula Xirakia; Konstantinos Varvagiannis; Georgios Boutsikas; Antonios Bilalis; Efstathios Kastritis; Athanasios Papatheodorou; Evangelos Terpos
Journal:  Haematologica       Date:  2009-05       Impact factor: 9.941

Review 5.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

Review 6.  Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.

Authors:  Andrea Giusti
Journal:  J Bone Miner Metab       Date:  2014-04-21       Impact factor: 2.626

Review 7.  Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review.

Authors:  M Mamtani; H Kulkarni
Journal:  Osteoporos Int       Date:  2009-02-26       Impact factor: 4.507

8.  Zoledronic Acid for Treatment of Low Bone Mineral Density in Patients with Beta Thalassemia Major.

Authors:  Rahul Naithani; Tulika Seth; Nikhil Tandon; Jagdish Chandra; V P Choudhry; H Pati; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-27       Impact factor: 0.900

9.  Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosis.

Authors:  Johann D Ringe
Journal:  Patient Prefer Adherence       Date:  2010-07-21       Impact factor: 2.711
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.